Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$2.76 - $4.64 $32,625 - $54,849
-11,821 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$4.09 - $7.16 $24,998 - $43,761
-6,112 Reduced 34.08%
11,821 $51,000
Q3 2021

Nov 12, 2021

BUY
$5.8 - $8.02 $16,808 - $23,241
2,898 Added 19.28%
17,933 $107,000
Q2 2021

Aug 13, 2021

BUY
$6.87 - $9.16 $23,763 - $31,684
3,459 Added 29.88%
15,035 $124,000
Q1 2021

May 14, 2021

SELL
$7.67 - $13.77 $9,288 - $16,675
-1,211 Reduced 9.47%
11,576 $99,000
Q4 2020

Feb 09, 2021

SELL
$12.07 - $17.95 $6,819 - $10,141
-565 Reduced 4.23%
12,787 $155,000
Q3 2020

Nov 13, 2020

BUY
$14.16 - $19.45 $16,538 - $22,717
1,168 Added 9.59%
13,352 $217,000
Q2 2020

Aug 03, 2020

BUY
$6.97 - $17.12 $84,922 - $208,590
12,184 New
12,184 $183,000
Q1 2020

May 15, 2020

SELL
$5.79 - $11.83 $78,118 - $159,610
-13,492 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$3.9 - $6.16 $52,618 - $83,110
13,492 New
13,492 $80,000
Q4 2017

Feb 14, 2018

SELL
$2.35 - $4.0 $67,680 - $115,200
-28,800 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$2.75 - $3.95 $7,023 - $10,088
2,554 Added 9.73%
28,800 $109,000
Q2 2017

Aug 11, 2017

BUY
N/A
26,246
26,246 $100,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $129M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.